Radezolid (INN, codenamed RX-1741) is a novel oxazolidinone antibiotic being developed by Rib-X Pharmaceuticals, Inc. for the treatment of serious multi-drug–resistant infections. Radezolid has completed two phase-II clinical trials. One of these clinical trials was for uncomplicated skin and skin-structure infections (uSSSI) and the other clinical trial was for community acquired pneumonia (CAP).
Zhou J, Bhattacharjee A, Chen S et al. (December 2008). "Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics". Bioorg. Med. Chem. Lett.18 (23): 6175–8. doi:10.1016/j.bmcl.2008.10.011. PMID18947996.CS1 maint: Explicit use of et al. (link)
Hanselmann R, Job G, Johnson G, Lou R, Martynow JG, Reeve MM (2009). "Synthesis of an antibacterial compound containing a 1,4-substituted 1H-1,2,3-triazole- a scaleable alternative to the "click" reaction"". Organic Process Research and Development14: 152–158. doi:10.1021/op900252a.